What systemic therapy, if any, would you recommend for a patient with oligometastatic melanoma who is rendered NED after resection?

This remains a very timely question and currently the data would allow for two options : observation vs adjuvant therapy with nivolumab.

Observation is a very reasonable option since we know that this can result in prolonged overall and occasionally relapse-free survival in a subset of patients; howe...